The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
LND did the strategic review at the wrong time when the gold price was depressed.
There will be much more interest now with gold breaking out to new all-time highs and producers will have lots more free cash on their balance sheets to purchase new projects
Got to be a screaming buy at such a low share price given the break out in the gold price.
The company has spent around £40 million on proving up the gold resource at BAM.
Whichever way you look at it, sub £5million market cap for an advanced gold project with a 1.5million in a safe jurisdiction has to be worth far more than that
As discussed recently the company is on the cusp of production. There is optionality over the large amount owed from the dale if the tantalum mine and the company has the full support of the new strategic shareholder whose interests are fully aligned with other shareholders
Not many are mentioning that HUM raised $28million recently. Most of the funds were received during January
The Corica underperformance has dragged on for several months so the company has very likely looked at bringing in replacements
If you properly put the drill results from Botswana into context they were highly encouraging considering it was only scout drilling. Also noteworthy were the results of drilling on the border of ARC's licence which suggests the mineralised zone runs across ARC's licence.
Not one a really follow, but I seem to recall KAV spending millions drilling in Botswana and not hitting any copper despite numerous attempts
Nvs was competent enough to get a very good JV over the line with Anglo American
The market hasn't attributed value to the JV deal so the directors are taking advantage of that IMO
It will be interesting to see how the Anglo drilling results play out to see if the the directors have called it right
I was looking at ANIC as an investment but the consultancy agreement with Shellbay is putting me off. I don't understand why the company had to pay around £3.5m in cash and shares. Last year the figure was nearly £5m. This is totally off-putting to potential investors. How can the directors justify such high fees being paid out each year?
I just had a quick look and it seems like the company burnt around $20million in cash during the second half of Q3.
With cash of just over $13million at the end of the year I would expect another fundraise around the time that the full-year results are published. The company obviously can't risk allowing it's cash holding to run too low before raising fresh funds
They probably won't take on another project for the time being. The priority will be to concentrate on production from the existing projects and realising the outstanding $8million from the sale of the tantalum project
As I pointed out earlier there won't be an equity raise as the company cannot issue new shares.
I don't know who has been selling recently or why, as it could be for a number of reasons and nothing to do with the prospects of Kazera. The market for the shares is very illiquid so a small amount of selling will have a disproportionate effect on the share price.
On the other hand if positive news is released the price could recover quickly if there is some decent buying pressure.
As an AIM traded UK registered company, Kazera Global plc is subject to the UK City Code on Takeovers and Mergers.
If AMS goes above 30% it has to make a mandatory takeover offer for the company at a price at least equal to the highest price it has paid for shares in the last 12 months i.e. 1.5p.
AMS recently paid £4.2million for a 30% stake in Kazera and I would have thought it would be very unlikely it would pay such a large amount unless it was certain that the company could be adequately funded.
There's lots of options if funds are required, not that I think there is currently any urgency, that don't require an issue of equity e.g.
Further funds received from the sale of the tantalum mine
Funds advanced by an offtake partner
Loan advanced from AMS as a strategic shareholder or a loan arranged by AMS